News
Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
We recently published These 10 Stocks Just Lost Their Spark. Abbott Laboratories (NYSE:ABT) is one of the worst-performing ...
Abbott did not factor in the decision during Sunday's loss to the Mets. He allowed two runs on six hits and a walk over six innings while striking out five.
Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...
Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...
Explore more
Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...
Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...
Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...
Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.
Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...
The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results